All Episodes
On The Pen GLP-1 News — 190 episodes
The Next Two Weeks in GLP1 Are Huge, Here's Why
He Took Retatrutide 40mg and Proved a Point
Eli Lilly Earnings Call Recap: Q1 2026
SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story
BPI STOPS TIRZEPATIDE Production, Second Major Pharmacy Out!
Retatrutide Could Change Everything… But Who Actually Gets It?
Ozempic Personality With Dr Spencer Nadolsky
Foundayo GLP-1 Pill: FDA Needs More Data
GLP-1 Access Is EXPLODING… But Something Else Is Happening
Zepbound Dosing: What Your Doctor Didn't Explain
Wegovy Price Drop Exposes a Bigger Problem
Retatrutide Is Too Good… And That’s The Problem
MASSIVE: Compound Tirzepatide and Semaglutide Updates!
Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch
Gray Market GLP-1 Is Booming Branded Access is Broken
UBT251 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
Wegovy vs Zepbound in 2026: New Higher Dose
Compound Tirzepatide: Time to Stock Up?
Eli Lilly Earnings Call Q4 2025 Recap
Once Monthly GLP-1 Injection? Pfizer Drops New Data
PCOS and Tirzepatide Clinical Trial. Finally
Over The Counter GLP-1 Prediction
GLP-1 PLUS Gastric Balloon for added Weight Loss!
GLP-1 Access, MariTide Data, and the Oprah Effect on Obesity Care
Wegovy Pens Recalled & Wegovy Pill Launch
Wegovy Pill Approved: First Ever GLP-1 Pill, As Good as Injections!
GLP-1 Compound Legislation: States are the Next Battlefield w/ Sabina Hemme
Compounded Retatrutide? What the Judge Said
Retatrutide Weight Loss: How Much At Each Dose
Mounjaro vs. New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight
GLP-1: New Metrics, New Molecules, New Prices
Novo Nordisk Amycretin Shocker + Semaglutide Flopper
Wegovy GLP-1 Price Novo Blinks First
GLP-1 State of the Union
Lower Cost Zepbound and Wegovy? TrumpRX Announcement Incoming
Eli Lilly Earnings Call Recap: NEW GLP-1 GIP Peptide Announced!
Retatrutide + Tirzepatide Grey Market Clampdown + 1 Billion GLP-1 Pills Incoming
HLTH 2025: Obesity Care Superstar Interviews
TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!
Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory
Retatrutide News That Could Change Everything for GLP-1 Compounds
Sobriety Meets Weight Loss: The Ethan Suplee Interview
Mounjaro Hair Loss + NFL Lineman Discovers Power in Personalized Medicine
Stopping Zepbound and Maintaining with Revita
GLP-1 Treatment and Advocacy with Dr. Leslie Golden
Pfizer GLP-1 Play Worth $7.3B + Compound Tirzepatide Update
GLP-1 Weight Loss, Why It's About So Much More for Patients
Compound GLP-1 Legislation + FDA Warning Letter to HIMS
FDA CRACKDOWN on Compounded GLP-1s | Novo’s Gut Hack & Lilly’s One-Shot Cure
Is Wegovy Better Than Zepbound? Plus the First Obesity GLP-1 Generic is Here!
Zepbound Compound Lawsuit Update: Eli Lilly Vs Mochi
Eli Lilly VS Mochi Update + Big Lilly Orforglipron Secret Revealed
Eli Lilly Orforglipron Secret Revealed! + Lill VS Mochi Update
Ozempic Price Cut + New Obesity Pill Data
GLP-1 Microdosing For Weight Loss: Noom CEO Explains Their New Program
Eli Lilly Earnings Call Recap: Stock Tanks on Weight Loss Pill Miss
Novo Nordisk Blames Compound Semaglutide on Slower Sales
No Compounded Retatrutide Says the FDA + Tons of GLP-1 News
LEAKED TRUMP DOCUMENT: Medicare to Cover Zepbound and Wegovy for Obesity
Retatrutide Drops are Crazy // OTP TWD 7.29.25
Compound GLP-1 Injections : You Won't Believe What The Obesity Society is Saying
Connecticut Making Ozempic!? Meet The Mastermind
SHOCKING: How GLP-1 Protects the Heart Beyond Weight Loss // OTP TWD 7.25.25
BREAKING: Insurance Approving Mounjaro Over Zepbound!? What is Going On!?
Behind the Scenes of the Obesity Drug Battle | Obesity Action Coalition President Interview
Unlocking Zepbound Insurance Coverage + More GLP-1 Good News // otp twd 7.1.25
Lilly Could Lose Their Tirzepatide Patent! Plus ADA Coverage // OTP TWD 06.24.25
Faces of The Fight: The Jamie Selzler Story
Zepbound Vials Drop, Amycretin Surges, FDA Fast Track, and a Dangerous Trend // TWD 6.17.25
GLP-1 Access Progress + The Race for Less Frequent Dosing: OTP TWD 6.10.25
Lilly Makes Bold Move on GLP Dosing / 8x More Ozempic? / Wegovy Use in Teens
Trump Admin Setting Price Targets for Zepbound and Ozempic, Will Pharma Go Along?
Zepbound vs. Wegovy, CVS vs. Patients, and the Executive Order That Changes Everything
Compound Tirzepatide Lawsuit + PBM Reform Update // OTP TWD 5.6.25
CVS Drops Zepbound + Lilly Earnings Call Recap
Compound GLP-1 PubMed Data: What It Didn’t Tell Us
High Dose Semaglutide Incoming! How Much Will it Cost? // OTP TWD 4.22.25
Getting Insurance To Cover Skin Removal Surgery // OTP Eps 109
Counterfeit Ozempic at Pharmacies! // OTP TWD 4.15.25
GLP-1 Slow Responders: Dr Matthea Rentea // OTP Eps 108
Grow-Zempic!? These Students Discoverd a GLP-1 Plant!
Noom CEO Geoff Cook Interview: Wall Street Journal GLP-1 Cost Ad
GLP-1 Medicare Coverage: What is Going On // OTP TWD 04.08.2025
Are GLP-1 Meds For Life? Fractyl’s CEO Says “Not So Fast!”
Fake Sugar: 👍 or 👎 for Weight Loss With Dr. Spencer Nadolsky // OTP Eps 107
Tirzepatide Compounds: Lilly Sues Pharmacies // OTP TWD 04.01.25
Zepbound Weight Loss Stalls: Tips and Tricks // OTP Eps 106
Rare Exclusive Interview: OFA Chairman Sits Down with OTP to Talk Tirzepatide Lawsuit
Novo’s Retatrutide Competitor
Ozempic: Setting the Microdosing Strategy Straight w/ Dr Tyna Moore // OTP EPS 105
Compound Tirzepatide Latest // Cagrisema Disappoints Again // Great Vikingtide News
Obesity Bias in Medicine With Dr. Toomer // OTP Eps 104
Compound GLP-1 Accessibility + World Obesity Day // OTP TWD 03.04.25
Compound Tirzepatide Latest Updates // @Mike.OnAMssion2 Joins // OTP Eps 103
Lilly Drops Zepbound Price, Compounders Sue FDA (again) OTP TWD 2.25.25
Compound Tirzepatide Lawsuit Update / GLP-1 Heart Health w Dr Simin Lee / OTP Eps 102
503A Compound Tirzepatide Deadline Is Here, What Next? // OTP TWD 2.18.25
Zepbound Weight Loss and Cancer Diagnosis // OTP Eps 101
Lilly Announces Next Gen Tirzepatide
GLP-1 Talk Show: An Emotional 100th On The Pen Live
Zepbound and Retatrutide News: Lilly Q4 Earnings Call Recap
Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications
Like Retatrutide But In A Pill? OTP TWD 2.4.25
463 Pound Zepbound Weight Loss // OTP Eps 99
503b Compounder Rocked by FDA Audit + OFA v FDA Trial Update
Kelly Matthew of GLP1 Real Talk Joins! OTP Eps 97
Massive Zepbound and Wegovy News // OTP TWD 1.21.25
TikTok GLP-1 Refugees Episode
Compounders Win Small Battle in War Over Zepbound and Mounjaro Shortages
Legal Expert: Compound Tirzepatide Trial Update || OTP Eps 96
Generic Liraglutide and GLP-1 Accessibility
More Generic GLP-1 Options Hit The Market!
On The Pen: The Weekly Dose 12.17.24
An Inflatable Stomach Balloon for Weight Loss
A GLP-1 Monopoly In The Making: Biden Admin Fails to Act, Novo Acquires Catalent
OFA Representation in Compound Tirzepatide Case Sits Down with OTP
CagriSema Delay? Novo Catalent Update
American Diabetes Association on the Wrong Side of Compounded GLP-1 Meds
Like Ozempic, But You Only Take It Once! Fractyl Health CEO Dr. Harith Rajagopalan
Retatrutide Cagrisema & Obesity Medicine Future With Dr. Michael Albert
Medicare to Cover Zepbound and Wegovy?
Compound Tirzepatide Future + @FitFlavorFun : OTP EPS 91
On The Pen: The Weekly Dose 11.19.24
CNN Special: Is Ozempic For You? With Dr. Gupta OTP REVIEW
Dr Spencer Nadolsky: Docs Who Lift Pod | OTP Eps 90
Novo Nordisk's War on Compound Semaglutide, Maritide Has Some Negative News
Viking Therapeutics and AstraZeneca Steal The Show at Obesity Week!
Lilly Earnings Call Analysis: Why Zepbound Missed Earnings
New Zepbound Savings Card, GLP-1 Accessibility Landscape Evolves
Inside the Legal Battle for Compound Tirzepatide: What You Need to Know from Industry Insider Scott Brunner!
Tirzepatide Lawsuits Filed By Lilly, Catalent Reframing Novo Merger
Compounded Zepbound Legal Battle Landscape: Legal Expert Weighs In
Compounded Zepbound Uncertainty + Leveraging GLP-1 To Improve Labor Shortages
Heartbreaking Zepbound Story | OTP Eps 85
Tirzepatide Lawsuits + Ozempic Patent Victory
Megadosing Zepbound and Mounjaro With Dr. Daniel Rosen
Ozempic and Zepbound Supply Impacted by Port Worker Strike!
Amy Kane @AmyInHalf Discusses Dramatic Mounjaro Transformation
On The Pen: The Weekly Dose 9.24.24
Eli Lilly Compound Tirzepatide Letters + Retatrutide Trial Guest!
BCBS Demanding Refunds From Ozempic Prescribers? | The Weekly Dose 9.17.24
On The Pen: The Weekly Dose 9.10.24
Dr. Spencer Nadolsky On Compound Tirzepatide After Leaving Weight Watchers
Ozempic Shortages Extended | The Weekly Dose 9.3.24
Zepbound Savings Card & Zepbound Vials Discussion With The Downsized
Massive Zepbound Vials News 8.27.24
On The Pen: The Weekly Dose 8.20.24
On The Pen: The Weekly Dose 8.13.24
On The Pen: The Weekly Dose 8.6.24
On The Pen: The Weekly Dose 7.30.24
On The Pen: The Weekly Dose 7.23.24
On The Pen: The Weekly Dose 7.16.24
Amylin and the future of obesity medicine with Dr. Beverly Tchang
On The Pen: The Weekly Dose 7.9.24
On The Pen: The Weekly Dose 7.2.24
On The Pen: The Weekly Dose 6.25.24
On The Pen: The Weekly Dose 6.18.24
Zepbound And Liver Disease
On The Pen: The Weekly Dose 6.11.24
On The Pen: The Weekly Dose 6.4.24
OTP EPS 68: Ro CEO Zach Reitano Talks GLP-1 Supply Tracker
On The Pen: The Weekly Dose 5.28.24
On The Pen Live Eps 67: Survodutide Trial Participant Tells All!
On The Pen: The Weekly Dose 5.21.24
On The Pen: The Weekly Dose 5.14.24
Threats to Lilly's Zepbound & Mounjaro Printing Press
On The Pen: The Weekly Dose 5.7.24
Lilly Earnings Call: Zepbound and Mounjaro Updates
On The Pen: The Weekly Dose 4/30/24
On The Pen: The Weekly Dose 4/23/24
Zepbound Vials: The Business Case
On The Pen: The Weekly Dose 4/16/24
Sourcing Compound Tirzepatide
On The Pen: The Weekly Dose 4.9.24
Zepbound Single Dose Vials Approved!
On The Pen: The Weekly Dose 3/26/24
On The Pen: The Weekly Dose 3/19/24
Novo Nordisk Pipeline Obesity Medicines Announced
On The Pen: The Weekly Dose 3/5/24
Mounjaro to Zepbound and Beyond with Dr. Albert
On The Pen: The Weekly Dose 2/27/24
On The Pen: The Weekly Dose 2/20/24
Zepbound Mounjaro Ozempic News: 2.13.24
Q4 Eli Lilly Earnings Call Recap
On The Pen: The Weekly Dose 2.6.24
Q4 Novo Nordisk Earnings Call Recap
On The Pen: The Weekly Dose 1.30.24
On The Pen: The Weekly Dose 1.23.24
On The Pen: The Weekly Dose 1.16.24
On The Pen: The Weekly Dose Podcast!